Abstract
Background: Simian virus-40 (SV40) is an efficient vector for gene therapy; however, it has not yet been used in the context of myocardial gene delivery. In contrast to adenovirus, which has generally been the vector of choice for many heart trials, SV40 does not elicit an immune response allowing repeated administrations, if necessary, to prolong the effect of the delivered gene. Furthermore, SV40 vectors are capable of infecting dividing or non-dividing cells. Our unique vector, prepared in vitro from recombinant SV40 capsid proteins and plasmid DNA, has no viral sequences, providing unique critical safety advantages. Therapeutic DNA of considerable size can be readily packaged into these vectors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
